The Surprise That Sent Vertex — And Its Chief Rival — Soaring

Vertex Pharmaceuticals (VRTX) reported positive Phase 2b results for inaxaplin in kidney disease, with a 45 mg once-daily regimen showing a safe profile. The company completed enrollment in the Phase 2/3 AMPLITUDE trial, aiming to diversify its pipeline beyond cystic fibrosis. Analysts forecast revenue of $17.2B and earnings of $6.5B by 2029, with potential upside if kidney and gene editing efforts succeed.

Vertex Pharmaceuticals (VRTX) reported Phase 2b AMPLIFIED results for inaxaplin in APOL1-mediated kidney disease, completing pivotal trial enrollment. Shares traded at $516.34, with mixed short-term performance. Analysts suggest undervaluation, with fair value estimates ranging from $558.68 to $681.83, citing pipeline diversification and long-term growth potential.

Maze Therapeutics (MAZE) stock rose 2.9% in pre-market trading after CIBC initiated coverage with an Outperformer rating and a $50 price target. The company has 13 buy-equivalent ratings. Vertex Pharmaceuticals' (VRTX) positive kidney disease data also boosted MAZE, as both companies work on APOL1 inhibitors. The S&P 500, Dow, and Nasdaq showed little movement, indicating the rally was driven by company-specific news.

Vertex Pharmaceuticals (VRTX) reported positive Phase 2b trial results for inaxaplin in treating APOL1-mediated kidney disease. The drug showed significant proteinuria reductions in two patient groups, with a favorable safety profile. Vertex expects interim Phase 2/3 trial results in early 2027, which could support U.S. approval. William Blair reiterated an Outperform rating, citing potential growth. VRTX shares rose 2.04% to $521.14.

Vertex Pharmaceuticals (VRTX) shares rose 3% after reporting positive trial results for inaxaplin in APOL1-mediated kidney disease (AMKD). The drug reduced protein leakage in urine by 42.7% for albumin and 44.7% for total protein in patients with modest proteinuria. Rival Maze Therapeutics (MAZE) shares jumped 25% on the read-through. Truist called the data a validation of APOL1 inhibition, estimating a market of over 100,000 patients and potential blockbuster sales for Maze's MZE829.

Vertex Pharmaceuticals (VRTX) reported positive Phase 2b results for Inaxaplin in additional patient groups with APOL1-mediated kidney disease, showing reductions in kidney damage markers. The company completed enrollment in its Phase 2/3 AMPLITUDE trial, with interim results expected in early 2027. Inaxaplin was generally safe and well-tolerated. VRTX stock is up 2.88% at $525.18.